{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:54Z","timestamp":1792801734968,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund","doi-asserted-by":"publisher","award":["24231222"],"award-info":[{"award-number":["24231222"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73944-x","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:54:56Z","timestamp":1780710896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Human angiotensin\u2011converting enzyme 2\u2011specific benzothiazole-based allosteric inhibitor against pan\u2011sarbecoviruses"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-7357","authenticated-orcid":false,"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence Tsz-Tai","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-8126","authenticated-orcid":false,"given":"Pok Man","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruomei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Yi","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz Tung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-1130","authenticated-orcid":false,"given":"Pui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-605X","authenticated-orcid":false,"given":"Kong Hung","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-9837","authenticated-orcid":false,"given":"Hin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4511-2888","authenticated-orcid":false,"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-5686","authenticated-orcid":false,"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"73944_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199\u20131207 (2020).","journal-title":"N. Engl. J. Med."},{"key":"73944_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"73944_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105354","volume":"108","author":"M Luo","year":"2024","unstructured":"Luo, M. et al. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants. EBioMedicine 108, 105354 (2024).","journal-title":"EBioMedicine"},{"key":"73944_CR4","doi-asserted-by":"publisher","unstructured":"Bellusci, L., Golding, H. & Khurana, S. Neutralizing activity of anti-SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants. J. Clin. Investig. 134, https:\/\/doi.org\/10.1172\/JCI182919 (2024).","DOI":"10.1172\/JCI182919"},{"key":"73944_CR5","doi-asserted-by":"publisher","first-page":"126966","DOI":"10.1016\/j.vaccine.2025.126966","volume":"54","author":"M Moore","year":"2025","unstructured":"Moore, M., Anderson, L., Schiffer, J. T., Matrajt, L. & Dimitrov, D. Durability of COVID-19 vaccine and infection induced immunity: a systematic review and meta-regression analysis. Vaccine 54, 126966 (2025).","journal-title":"Vaccine"},{"key":"73944_CR6","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/S1473-3099(24)00810-7","volume":"25","author":"K Uriu","year":"2025","unstructured":"Uriu, K. et al. Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC. Lancet Infect. Dis. 25, e61 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"73944_CR7","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1016\/S1473-3099(24)00688-1","volume":"24","author":"P Arora","year":"2024","unstructured":"Arora, P. et al. Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC. Lancet Infect. Dis. 24, e732\u2013e733 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"73944_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","volume":"583","author":"TT Lam","year":"2020","unstructured":"Lam, T. T. et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 583, 282\u2013285 (2020).","journal-title":"Nature"},{"key":"73944_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41586-020-2313-x","volume":"583","author":"K Xiao","year":"2020","unstructured":"Xiao, K. et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature 583, 286\u2013289 (2020).","journal-title":"Nature"},{"key":"73944_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21240-1","volume":"12","author":"S Wacharapluesadee","year":"2021","unstructured":"Wacharapluesadee, S. et al. Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nat. Commun. 12, 972 (2021).","journal-title":"Nat. Commun."},{"key":"73944_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1080\/22221751.2021.1964925","volume":"10","author":"LL Li","year":"2021","unstructured":"Li, L. L. et al. A novel SARS-CoV-2 related coronavirus with complex recombination isolated from bats in Yunnan province, China. Emerg. Microbes Infect. 10, 1683\u20131690 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"73944_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"73944_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"W Li","year":"2005","unstructured":"Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676\u2013679 (2005).","journal-title":"Science"},{"key":"73944_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nature12711","volume":"503","author":"X-Y Ge","year":"2013","unstructured":"Ge, X.-Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535\u2013538 (2013).","journal-title":"Nature"},{"key":"73944_CR15","doi-asserted-by":"publisher","first-page":"e1006698","DOI":"10.1371\/journal.ppat.1006698","volume":"13","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 13, e1006698 (2017).","journal-title":"PLoS Pathog."},{"key":"73944_CR16","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1128\/mBio.00208-10","volume":"1","author":"P-L Quan","year":"2010","unstructured":"Quan, P.-L. et al. Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria. mBio 1, e00208\u2013e00210 (2010).","journal-title":"mBio"},{"key":"73944_CR17","doi-asserted-by":"publisher","first-page":"14040","DOI":"10.1073\/pnas.0506735102","volume":"102","author":"SK Lau","year":"2005","unstructured":"Lau, S. K. et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA 102, 14040\u201314045 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73944_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508\u20131513 (2015).","journal-title":"Nat. Med."},{"key":"73944_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/acsptsci.2c00003","volume":"5","author":"K Dutta","year":"2022","unstructured":"Dutta, K. Allosteric Site of ACE-2 as a Drug Target for COVID-19. ACS Pharmacol. Transl. Sci. 5, 179\u2013182 (2022).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"73944_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16048-4","volume":"11","author":"C Lei","year":"2020","unstructured":"Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 11, 2070 (2020).","journal-title":"Nat. Commun."},{"key":"73944_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41589-021-00965-6","volume":"18","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. Nat. Chem. Biol. 18, 342\u2013351 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"73944_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1126\/science.abd9909","volume":"370","author":"L Cao","year":"2020","unstructured":"Cao, L. et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 370, 426\u2013431 (2020).","journal-title":"Science"},{"key":"73944_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905\u2013913.e7 (2020).","journal-title":"Cell"},{"key":"73944_CR24","doi-asserted-by":"publisher","unstructured":"Chan, K. K., Tan, T. J. C., Narayanan, K. K. & Procko, E. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. Sci. Adv. 7, https:\/\/doi.org\/10.1126\/sciadv.abf1738 (2021).","DOI":"10.1126\/sciadv.abf1738"},{"key":"73944_CR25","doi-asserted-by":"publisher","first-page":"eadi2623","DOI":"10.1126\/scitranslmed.adi2623","volume":"15","author":"E Urano","year":"2023","unstructured":"Urano, E. et al. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models. Sci. Transl. Med. 15, eadi2623 (2023).","journal-title":"Sci. Transl. Med."},{"key":"73944_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41564-023-01389-9","volume":"8","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies. Nat. Microbiol. 8, 1051\u20131063 (2023).","journal-title":"Nat. Microbiol."},{"key":"73944_CR27","doi-asserted-by":"publisher","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","volume":"318","author":"AM South","year":"2020","unstructured":"South, A. M., Diz, D. I. & Chappell, M. C. COVID-19, ACE2, and the cardiovascular consequences. Am. J. Physiol. Heart Circ. Physiol. 318, H1084\u2013H1090 (2020).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"73944_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue, M. et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, e1\u2013e9 (2000).","journal-title":"Circ. Res."},{"key":"73944_CR29","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","volume":"275","author":"SR Tipnis","year":"2000","unstructured":"Tipnis, S. R. et al. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238\u201333243 (2000).","journal-title":"J. Biol. Chem."},{"key":"73944_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110678","volume":"131","author":"M Dong","year":"2020","unstructured":"Dong, M. et al. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed. Pharmacother. 131, 110678 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"73944_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631\u2013637 (2004).","journal-title":"J. Pathol."},{"key":"73944_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejmech.2014.02.007","volume":"76","author":"X Xie","year":"2014","unstructured":"Xie, X., Yan, Y., Zhu, N. & Liu, G. Benzothiazoles exhibit broad-spectrum antitumor activity: their potency, structure-activity and structure-metabolism relationships. Eur. J. Med. Chem. 76, 67\u201378 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"73944_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21767-3","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution. Nat. Commun. 12, 1607 (2021).","journal-title":"Nat. Commun."},{"key":"73944_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"73944_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","volume":"6","author":"MM Zhao","year":"2021","unstructured":"Zhao, M. M. et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct. Target. Ther. 6, 134 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"73944_CR36","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41589-022-01059-7","volume":"18","author":"BJ Fraser","year":"2022","unstructured":"Fraser, B. J. et al. Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation. Nat. Chem. Biol. 18, 963\u2013971 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"73944_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3\u201320 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"73944_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1023\/A:1013302231549","volume":"21","author":"C Dalvit","year":"2001","unstructured":"Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M. & Stockman, B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 21, 349\u2013359 (2001).","journal-title":"J. Biomol. NMR"},{"key":"73944_CR39","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1021\/ja0100120","volume":"123","author":"M Mayer","year":"2001","unstructured":"Mayer, M. & Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 123, 6108\u20136117 (2001).","journal-title":"J. Am. Chem. Soc."},{"key":"73944_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01492-21","volume":"96","author":"W Ren","year":"2022","unstructured":"Ren, W. et al. Susceptibilities of human ACE2 genetic variants in coronavirus infection. J. Virol. 96, e0149221 (2022).","journal-title":"J. Virol."},{"key":"73944_CR41","doi-asserted-by":"publisher","first-page":"22311","DOI":"10.1073\/pnas.2010146117","volume":"117","author":"J Damas","year":"2020","unstructured":"Damas, J. et al. Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. Proc. Natl. Acad. Sci. USA 117, 22311\u201322322 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73944_CR42","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 181, 894\u2013904.e9 (2020).","journal-title":"Cell"},{"key":"73944_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"73944_CR44","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"F Li","year":"2005","unstructured":"Li, F., Li, W., Farzan, M. & Harrison, S. C. J. S. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864\u20131868 (2005).","journal-title":"Science"},{"key":"73944_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"73944_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2016.01.007","volume":"774","author":"S Joshi","year":"2016","unstructured":"Joshi, S., Balasubramanian, N., Vasam, G. & Jarajapu, Y. P. Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. Eur. J. Pharmacol. 774, 25\u201333 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"73944_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16935-w","volume":"11","author":"T Tayri-Wilk","year":"2020","unstructured":"Tayri-Wilk, T. et al. Mass spectrometry reveals the chemistry of formaldehyde cross-linking in structured proteins. Nat. Commun. 11, 3128 (2020).","journal-title":"Nat. Commun."},{"key":"73944_CR48","doi-asserted-by":"publisher","first-page":"e0024922","DOI":"10.1128\/jvi.00249-22","volume":"96","author":"Q Geng","year":"2022","unstructured":"Geng, Q. et al. Structural basis for human receptor recognition by SARS-CoV-2 Omicron variant BA. 1. J. Virol. 96, e0024922 (2022).","journal-title":"J. Virol."},{"key":"73944_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28528-w","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. Nat. Commun. 13, 871 (2022).","journal-title":"Nat. Commun."},{"key":"73944_CR50","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Antibody evasion by the P. 1 strain of SARS-CoV-2. Cell 184, 2939\u20132954.e9 (2021).","journal-title":"Cell"},{"key":"73944_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00822-23","volume":"97","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. Structural evolution of SARS-CoV-2 omicron in human receptor recognition. J. Virol. 97, e0082223 (2023).","journal-title":"J. Virol."},{"key":"73944_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41421-021-00349-z","volume":"7","author":"S Xia","year":"2021","unstructured":"Xia, S. et al. Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B. 1.1. 7 variant (Alpha). Cell Discov. 7, 109 (2021).","journal-title":"Cell Discov."},{"key":"73944_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38435-3","volume":"14","author":"T Tamura","year":"2023","unstructured":"Tamura, T. et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat. Commun. 14, 2800 (2023).","journal-title":"Nat. Commun."},{"key":"73944_CR54","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","volume":"24","author":"W Li","year":"2005","unstructured":"Li, W. et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24, 1634\u20131643 (2005).","journal-title":"EMBO J."},{"key":"73944_CR55","doi-asserted-by":"publisher","first-page":"e1009392","DOI":"10.1371\/journal.ppat.1009392","volume":"17","author":"W Ren","year":"2021","unstructured":"Ren, W. et al. Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. PLoS Pathog. 17, e1009392 (2021).","journal-title":"PLoS Pathog."},{"key":"73944_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38201-5","volume":"14","author":"R Xie","year":"2023","unstructured":"Xie, R. et al. Resurgence of omicron BA. 2 in SARS-CoV-2 infection-naive Hong Kong. Nat. Commun. 14, 2422 (2023).","journal-title":"Nat. Commun."},{"key":"73944_CR57","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"73944_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"73944_CR59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/d41586-023-00347-z","volume":"614","author":"E Callaway","year":"2023","unstructured":"Callaway, E. COVID drug drives viral mutations\u2014and now some want to halt its use. Nature 614, 399\u2013399 (2023).","journal-title":"Nature"},{"key":"73944_CR60","doi-asserted-by":"publisher","unstructured":"Heilmann, E. et al. SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci. Transl. Med. 15, https:\/\/doi.org\/10.1126\/scitranslmed.abq7360 (2023).","DOI":"10.1126\/scitranslmed.abq7360"},{"key":"73944_CR61","doi-asserted-by":"publisher","unstructured":"Tamura, T. J. et al. Emerging SARS-CoV-2 resistance after antiviral treatment. JAMA Netw. Open 7, https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35431 (2024).","DOI":"10.1001\/jamanetworkopen.2024.35431"},{"key":"73944_CR62","doi-asserted-by":"publisher","unstructured":"Zhang, L. et al. Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04. Cell Discov. 10, https:\/\/doi.org\/10.1038\/s41421-024-00673-0 (2024).","DOI":"10.1038\/s41421-024-00673-0"},{"key":"73944_CR63","doi-asserted-by":"publisher","unstructured":"Moghadasi, S. A. et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci. Adv. 9, https:\/\/doi.org\/10.1126\/sciadv.ade8778 (2023).","DOI":"10.1126\/sciadv.ade8778"},{"key":"73944_CR64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73944_CR65","doi-asserted-by":"publisher","unstructured":"Yang, K. et al. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein. Proc. Natl. Acad. Sci. USA 119, https:\/\/doi.org\/10.1073\/pnas.2210990119 (2022).","DOI":"10.1073\/pnas.2210990119"},{"key":"73944_CR66","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1021\/acscentsci.3c00313","volume":"9","author":"S Xue","year":"2023","unstructured":"Xue, S. et al. An HR2-mimicking sulfonyl-\u03b3-AApeptide is a potent pan-coronavirus fusion inhibitor with strong blood-brain barrier permeability, long half-life, and promising oral bioavailability. ACS Cent. Sci. 9, 1046\u20131058 (2023).","journal-title":"ACS Cent. Sci."},{"key":"73944_CR67","doi-asserted-by":"crossref","unstructured":"Ohashi, H. et al. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24, 102367 (2021).","DOI":"10.1016\/j.isci.2021.102367"},{"key":"73944_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104528","volume":"25","author":"S Ding","year":"2022","unstructured":"Ding, S. et al. VE607 stabilizes SARS-CoV-2 Spike in the \u201cRBD-up\u201d conformation and inhibits viral entry. iScience 25, 104528 (2022).","journal-title":"iScience"},{"key":"73944_CR69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.antiviral.2006.04.014","volume":"74","author":"T-Y Ho","year":"2007","unstructured":"Ho, T.-Y., Wu, S.-L., Chen, J.-C., Li, C.-C. & Hsiang, C.-Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antivir. Res. 74, 92\u2013101 (2007).","journal-title":"Antivir. Res."},{"key":"73944_CR70","doi-asserted-by":"publisher","first-page":"e01622-20","DOI":"10.1128\/JVI.01622-20","volume":"95","author":"A Milewska","year":"2021","unstructured":"Milewska, A. et al. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV. J. Virol. 95, e01622-20 (2021).","journal-title":"J. Virol."},{"key":"73944_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153591","volume":"87","author":"LJ Yang","year":"2021","unstructured":"Yang, L. J. et al. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Phytomedicine 87, 153591 (2021).","journal-title":"Phytomedicine"},{"key":"73944_CR72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s42003-023-04789-z","volume":"6","author":"PS Kwon","year":"2023","unstructured":"Kwon, P. S. et al. Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions. Commun. Biol. 6, 387 (2023).","journal-title":"Commun. Biol."},{"key":"73944_CR73","doi-asserted-by":"publisher","unstructured":"Xing, L. et al. Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.01.012 (2025).","DOI":"10.1016\/j.cell.2025.01.012"},{"key":"73944_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.105994","volume":"176","author":"O Omotuyi","year":"2023","unstructured":"Omotuyi, O. et al. Benzimidazole compound abrogates SARS-COV-2 receptor-binding domain (RBD)\/ACE2 interaction in vitro. Micro. Pathog. 176, 105994 (2023).","journal-title":"Micro. Pathog."},{"key":"73944_CR75","doi-asserted-by":"publisher","first-page":"17996","DOI":"10.1074\/jbc.M311191200","volume":"279","author":"P Towler","year":"2004","unstructured":"Towler, P. et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 279, 17996\u201318007 (2004).","journal-title":"J. Biol. Chem."},{"key":"73944_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52808-2","volume":"15","author":"H Yajima","year":"2024","unstructured":"Yajima, H. et al. Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1. Nat. Commun. 15, 8574 (2024).","journal-title":"Nat. Commun."},{"key":"73944_CR77","doi-asserted-by":"publisher","first-page":"e0034224","DOI":"10.1128\/jvi.00342-24","volume":"98","author":"S Qiao","year":"2024","unstructured":"Qiao, S. & Wang, X. Structural determinants of spike infectivity in bat SARS-like coronaviruses RsSHC014 and WIV1. J. Virol. 98, e0034224 (2024).","journal-title":"J. Virol."},{"key":"73944_CR78","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"73944_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18387-8","volume":"11","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat. Commun. 11, 4528 (2020).","journal-title":"Nat. Commun."},{"key":"73944_CR80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2509616122","volume":"122","author":"Z Wan","year":"2025","unstructured":"Wan, Z. et al. Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy. Proc. Natl. Acad. Sci. USA 122, e2509616122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73944_CR81","doi-asserted-by":"publisher","unstructured":"Rea-Moreno, M. et al. Unveiling alternate pathways for SARS-CoV-2 infection via extracellular vesicle-mediated transfer of ACE2 and TMPRSS2. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-026-71680-w (2026).","DOI":"10.1038\/s41467-026-71680-w"},{"key":"73944_CR82","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","volume":"53","author":"R Zhou","year":"2020","unstructured":"Zhou, R. et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 53, 864\u2013877.e5 (2020).","journal-title":"Immunity"},{"key":"73944_CR83","doi-asserted-by":"publisher","first-page":"e1012625","DOI":"10.1371\/journal.ppat.1012625","volume":"20","author":"H Dong","year":"2024","unstructured":"Dong, H. et al. Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1. PLoS Pathog. 20, e1012625 (2024).","journal-title":"PLoS Pathog."},{"key":"73944_CR84","doi-asserted-by":"publisher","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, https:\/\/doi.org\/10.1172\/jci.insight.123158 (2019).","DOI":"10.1172\/jci.insight.123158"},{"key":"73944_CR85","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1080\/22221751.2020.1791738","volume":"9","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg. Microbes Infect. 9, 1664\u20131670 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"73944_CR86","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","volume":"1","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe 1, e14\u2013e23 (2020).","journal-title":"Lancet Microbe"},{"key":"73944_CR87","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41392-022-01241-2","volume":"7","author":"Y Hou","year":"2022","unstructured":"Hou, Y. et al. Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids. Signal Transduct. Target. Ther. 7, 381 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"73944_CR88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1021\/cc060034o","volume":"9","author":"G Liu","year":"2007","unstructured":"Liu, G. et al. Benzofused tricycles based on 2-quinoxalinol. J. Comb. Chem. 9, 70\u201378 (2007).","journal-title":"J. Comb. Chem."},{"key":"73944_CR89","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1128\/AAC.05537-11","volume":"56","author":"X Lu","year":"2012","unstructured":"Lu, X. et al. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Antimicrob. Agents Chemother. 56, 341\u2013351 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73944_CR90","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/mi.2015.127","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunol. 9, 1089\u20131101 (2016).","journal-title":"Mucosal Immunol."},{"key":"73944_CR91","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.chom.2021.02.019","volume":"29","author":"D Zhou","year":"2021","unstructured":"Zhou, D. et al. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. J. Cell Host Microbe 29, 551\u2013563.e5 (2021).","journal-title":"J. Cell Host Microbe"},{"key":"73944_CR92","doi-asserted-by":"publisher","first-page":"103762","DOI":"10.1016\/j.ebiom.2021.103762","volume":"75","author":"R Zhou","year":"2022","unstructured":"Zhou, R. et al. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine 75, 103762 (2022).","journal-title":"EBioMedicine"},{"key":"73944_CR93","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","volume":"593","author":"S Yuan","year":"2021","unstructured":"Yuan, S. et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature 593, 418\u2013423 (2021).","journal-title":"Nature"},{"key":"73944_CR94","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu, C. et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. J. Chem. Theory Comput. 17, 4291\u20134300 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"73944_CR95","doi-asserted-by":"crossref","unstructured":"Shuai, H. et al. An orally available Mpro\/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo. Nat. Commun. 16, 6541 (2025).","DOI":"10.1038\/s41467-025-60832-z"},{"key":"73944_CR96","doi-asserted-by":"publisher","first-page":"104916","DOI":"10.1016\/j.ebiom.2023.104916","volume":"99","author":"B Hu","year":"2024","unstructured":"Hu, B. et al. Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2\/5 subvariants in the upper and lower respiratory tract. EBioMedicine 99, 104916 (2024).","journal-title":"EBioMedicine"},{"key":"73944_CR97","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41586-022-05148-4","volume":"609","author":"H Chu","year":"2022","unstructured":"Chu, H. et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature 609, 785\u2013792 (2022).","journal-title":"Nature"},{"key":"73944_CR98","doi-asserted-by":"publisher","first-page":"eadd3867","DOI":"10.1126\/sciadv.add3867","volume":"9","author":"JF Chan","year":"2023","unstructured":"Chan, J. F. et al. Altered host protease determinants for SARS-CoV-2 Omicron. Sci. Adv. 9, eadd3867 (2023).","journal-title":"Sci. Adv."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73944-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73944-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73944-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:01:51Z","timestamp":1785124911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73944-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73944"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73944-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.L., W.Y., L.L. and Z.C. are listed as inventors on a patent application filed by Ningbo Combireg Pharmaceutical Technology Co., Ltd. and The University of Hong Kong (provisional application number: CN202310158328.5, PCT\/CN2023\/077984), which covers the use of the MB-32 and its analogs in antiviral infection. G.L. is a co-founder of Ningbo Combireg Pharmaceutical Technology Co., Ltd., Zhejiang, PR China. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7224"}}